Scholar Rock

Develops antibody medicines that selectively block activation of latent growth factors, with a strategic focus on rare neuromuscular diseases. Apitegromab, an investigational myostatin inhibitor, has completed a successful pivotal study in spinal muscular atrophy and is under U.S. and European regulatory review. Studies in younger SMA patients and facioscapulohumeral muscular dystrophy, a subcutaneous apitegromab formulation, and SRK-439 extend the anti-myostatin pipeline.

Prepares for potential launches in the United States and Europe while seeking partners for oncology, fibrosis, anemia, and weight-loss combination programs. No product has been approved or generated product sales. Commercialization depends on regulatory clearance, reimbursement, and third-party manufacturing; following an adverse inspection classification at the original fill-finish provider, the U.S. application is proceeding with an alternate facility.